Citadel Advisors
PYXS icon

Citadel Advisors’s Pyxis Oncology PYXS Stock Holding History

Citadel Advisors’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Sell
47,317
-13,932
-23% -$26.6K ﹤0.01% 12394
2026
Q1 		$89.4K Sell
61,249
-182,340
-75% -$275K ﹤0.01% 12106
2025
Q4 		$280K Sell
243,589
-93,770
-28% -$331K ﹤0.01% 10286
2025
Q3 		$749K Buy
+337,359
New +$486K ﹤0.01% 8181
2024
Q4 		– Sell
-275,951
Closed -$796K – 15213
2024
Q3 		$1.01M Buy
+275,951
New +$966K ﹤0.01% 6845
2024
Q2 		– Sell
-4,109
Closed -$17.3K – 15178
2024
Q1 		$17.5K Sell
4,109
-102,726
-96% -$432K ﹤0.01% 13097
2023
Q4 		$192K Buy
+106,835
New +$183K ﹤0.01% 10016
2023
Q2 		– Sell
-27,129
Closed -$109K – 15062
2023
Q1 		$109K Sell
27,129
-1,535,669
-98% -$3.07M ﹤0.01% 11132
2022
Q4 		$2.09M Buy
1,562,798
+32,013
+2% +$48K ﹤0.01% 5404
2022
Q3 		$3.02M Buy
1,530,785
+9,849
+0.6% +$25.7K ﹤0.01% 4801
2022
Q2 		$3.62M Sell
1,520,936
-1,562
-0.1% -$4.16K ﹤0.01% 4415
2022
Q1 		$6.06M Buy
1,522,498
+881
+0.1% +$6.44K ﹤0.01% 3810
2021
Q4 		$16.5M Buy
+1,521,617
New +$17.4M ﹤0.01% 2273

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's PYXS Position: Q2 2026 in Review

Citadel Advisors reduced its Pyxis Oncology (PYXS) stake by 23% in Q2 2026, selling an estimated $26.6K and leaving 47,317 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #12394.

Citadel Advisors first reported a position in PYXS in Q4 2021 and has held it in 13 quarters since. The position peaked at $16.5M in Q4 2021. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Citadel Advisors held 47,317 shares of Pyxis Oncology worth $142K as of Q2 2026.
  • Citadel Advisors sold 13,932 Pyxis Oncology shares in Q2 2026, an estimated $26.6K.
  • Pyxis Oncology made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12394 holding.
  • Citadel Advisors first reported a position in Pyxis Oncology in Q4 2021 and has held it in 13 quarters since.
  • Citadel Advisors's Pyxis Oncology position peaked at $16.5M in Q4 2021.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.